Security
Dyne Therapeutics, Inc. · DYN
DYNNASDAQCommon stockCurrentCIK 1818794Updated Oct 7, 2026
DYN price & chart
Loading TradingView…
NASDAQ:DYN on TradingView ↗About the company
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
In the news
Dyne Therapeutics to Participate in Upcoming Investor Conferences ↗
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN News provided by DJS Law Group LLP Jun 24, 2025, 03:43 ET Share this article Share to X Share this article Share to X LOS ANGELES , June 24, 2025 /PRNewswire/ -- The DJS Law Group ↗
Recent filings
4 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
144 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,186,958,000Source | 691,234,000Source | 165,082,000Source | 306,325,000Source |
| Property, Plant and Equipment, NetUSD | 24,029,000Source | 5,398,000Source | 4,780,000Source | 5,945,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 893,369,000Source | 435,449,000Source | 121,626,000Source | 172,147,000Source |
| Assets, CurrentUSD | 1,126,587,000Source | 659,279,000Source | 129,375,000Source | 265,594,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 16,025,000Source | 17,011,000Source | 6,275,000Source | 9,582,000Source |
| Operating Lease, Right-of-Use AssetUSD | 20,742,000Source | 24,615,000Source | 28,612,000Source | 32,467,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 214,829,000Source | 61,396,000Source | 73,790,000Source | 53,961,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 16,000Source | 10,000Source | 6,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 2,367,780,000Source | 1,579,750,000Source | 723,796,000Source | 649,502,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,396,142,000Source | -949,928,000Source | -632,510,000Source | -396,573,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 475,000Source | 6,000Source | 0Source | -571,000Source |
| Stockholders' Equity Attributable to ParentUSD | 972,129,000Source | 629,838,000Source | 91,292,000Source | 252,364,000Source |
| Liabilities and EquityUSD | 1,186,958,000Source | 691,234,000Source | 165,082,000Source | 306,325,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 50,625,000Source | 42,258,000Source | 51,095,000Source | 28,088,000Source |
| Operating Lease, Liability, CurrentUSD | 4,995,000Source | 4,850,000Source | 4,720,000Source | 4,610,000Source |
| Accounts Payable, CurrentUSD | 8,082,000Source | 6,562,000Source | 22,936,000Source | 5,259,000Source |
| Operating Lease, Liability, NoncurrentUSD | 15,283,000Source | 19,138,000Source | 22,695,000Source | 25,873,000Source |
| Additional Financial Items | ||||
| Long-term DebtUSD | 148,921,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -446,214,000Source | -317,418,000Source | -235,937,000Source | -168,099,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,049,000Source | 1,673,000Source | 1,673,000Source | 1,683,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 45,851,000Source | 45,864,000Source | 19,972,000Source | 15,178,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -403,207,000Source | -292,369,000Source | -188,158,000Source | -153,645,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -28,751,000Source | -204,076,000Source | 83,311,000Source | 87,202,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,920,000Source | 2,376,000Source | 729,000Source | 3,067,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 890,307,000Source | 809,895,000Source | 54,322,000Source | 37,390,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 458,349,000Source | 313,450,000Source | -50,525,000Source | -29,053,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 895,740,000Source | 437,391,000Source | 123,941,000Source | 174,466,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,339,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 45,851,000Source | 45,864,000Source | 19,972,000Source | 15,178,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -95,000Source | -72,000Source | -118,000Source | — |
| General and Administrative ExpenseUSD | 69,851,000Source | 62,480,000Source | 31,400,000Source | 28,202,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -446,214,000Source | -317,418,000Source | -235,937,000Source | -168,099,000Source |
| Operating ExpensesUSD | 468,184,000Source | 343,886,000Source | 242,162,000Source | 170,962,000Source |
| Other Nonoperating Income (Expense)USD | 21,970,000Source | 26,468,000Source | 6,225,000Source | 2,863,000Source |
| Other Operating Income (Expense), NetUSD | -1,697,000Source | -454,000Source | -1,416,000Source | -54,000Source |
| Proceeds from Issuance of Common StockUSD | 140,653,000Source | 97,871,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | 148,256,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 7,999,000Source | 36,844,000Source | 1,953,000Source | 529,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -468,184,000Source | -343,886,000Source | -242,162,000Source | -170,962,000Source |
| Other Nonoperating Income (Expense)USD | 21,970,000Source | 26,468,000Source | 6,225,000Source | 2,863,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -446,214,000Source | -317,418,000Source | -235,937,000Source | -168,099,000Source |
| Earnings Per Share, BasicUSD per share | -3.47Source | -3.37Source | -3.95Source | -3.23Source |
| Earnings Per Share, DilutedUSD per share | -3.47Source | -3.37Source | -3.95Source | -3.23Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 69,851,000Source | 62,480,000Source | 31,400,000Source | 28,202,000Source |
| Interest Income, OtherUSD | 29,859,000Source | 26,922,000Source | 7,641,000Source | 2,917,000Source |
| Labor and Related ExpenseUSD | 86,467,000Source | 63,321,000Source | — | — |
| Operating ExpensesUSD | 468,184,000Source | 343,886,000Source | 242,162,000Source | 170,962,000Source |
| Other Operating Income (Expense), NetUSD | -1,697,000Source | -454,000Source | -1,416,000Source | -54,000Source |
| Research and Development ExpenseUSD | 398,333,000Source | 281,406,000Source | 210,762,000Source | 142,760,000Source |
Filing attachments
dyn-ex99_1.htm · 8-K · 2026-09-29
Exhibit 99.1 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months - - Data continued to support improvement at 6 months in video …
Read attachment ↗dyn-ex99_2.htm · 8-K · 2026-09-29
Z-Basivarsen Addresses the Central Pathobiology of DM1 to Enable Broad Functional Improvement1 3 Muscle Strength: Quantitative Muscle Testing Timed-Function Tests: 5 Times Sit to Stand; 10-Meter Walk / Run Patient-Reported Outcomes: Myotonic Dystrophy Health Index (MDHI) Robust and widespread delivery DMPK degradation in the nucleus MBNL release and splicing correction MBNL trapped: Splicing defect CUG expansion MBNL released: Splicing corrected Differentiated MOA Z-basivarsen Relevant tissue di…
Read attachment ↗dyn-ex99_1.htm · 8-K · 2026-07-29
EX-99.1 2 dyn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment of 71 participants in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1; topline data planned for Q1 2027 - - I…
Read attachment ↗d112911dex991.htm · 8-K · 2026-07-22
EX-99.1 4 d112911dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a p…
Read attachment ↗dyn-ex99_1.htm · 8-K · 2026-06-03
EX-99.1 2 dyn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 3, 2026 - Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neur…
Read attachment ↗dyn-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 dyn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA conference - - Completion of enrollment in regi…
Read attachment ↗